Although the incidence and percentage of litters with resorptions was not significantly affected by PFDA treatment (Table 3), three litters had 100% resorptions at the highest exposure group compared to zero for the controls, which is considered biologically significant.

"The number of live fetuses per litter was significantly decreased only at a PFDA dose of 12.8 mg PFDA/kg body wt/ day. Three litters had 100% fetal mortality significantly decreased only at a PFDA dose of 12.8 mg PFDA/kg body wt/ day. Three litters had 100% fetal mortality at this dose. A significant decrease (p < 0.05) in live fetal weight was evident at a maternal dose of 0.1 mg PFDA/kg body wt/day and a highly significant (p < 0.0 1) decrease in live fetal weight was observed at maternal doses of 3.0,6.4, and 12.8 mg PFDA/kg/day. A significant dose-related increase (p < 0.05) in percentage fetal mortality was observed, but only in litters where significant maternal toxicity was observed (6.4 and 12.8 mg/kg/day). No induction of hydronephrosis or cleft palate was observed in fetuses at any level tested. No other soft tissue malformations were observed. No skeletal malformations were found. Variations in ossification of braincase were observed in 100% of fetuses examined at a maternal dose of 12.8 mg PFDA/kg/day (Table 4)."

F1 C57BL/6N Mice